Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ESA title
Pharmacological Countermeasures - SciSpacE

Pharmacological Countermeasures

Despite decades of human space missions, there are known unknowns regarding pharmacological countermeasures (PCMs) that have not yet been satisfactorily resolved, many of which are centred on the potential effects of spaceflight-altered physiology on the handling and action of administered medications. This is also a key point of crosslinking with most of the other disciplines. Other issues centre on the medication supply since re-supply opportunities will be limited as distance from Earth increases. Current PCMs must be re-evaluated, both for suitability in new mission scenarios and updated as new terrestrial therapies are developed. Additionally, new hazards, like exposure to planetary dust, will necessitate new countermeasures.

The multidisciplinary Topical Team will investigate:

  • Effects of space-altered physiology on pharmacokinetics, pharmacodynamics, drug interaction, drug-nutrition interaction, drug-microbiota interactions, and drug physical therapies interaction issues
  • Mitigating medication-related problems in relation to medication use, medication supply and long-acting/personalized dosage forms
  • Coping with emerging hazards such as deep space radiation, planetary hazards, and newly recognized risks to humans in space
  • Optimization of existing pharmacological countermeasures via personalized medicine options, such as pharmacogenomics and update treatments used in space as per new terrestrial treatments, also solve regulatory issues on medication in space